Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging
Hanjun Li, … , Zhengju Yao, Xizhi Guo
Hanjun Li, … , Zhengju Yao, Xizhi Guo
Published February 27, 2017
Citation Information: J Clin Invest. 2017;127(4):1241-1253. https://doi.org/10.1172/JCI89511.
View: Text | PDF | Corrigendum
Research Article Aging

FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging

  • Text
  • PDF
Abstract

A hallmark of aged mesenchymal stem/progenitor cells (MSCs) in bone marrow is the pivot of differentiation potency from osteoblast to adipocyte coupled with a decrease in self-renewal capacity. However, how these cellular events are orchestrated in the aging progress is not fully understood. In this study, we have used molecular and genetic approaches to investigate the role of forkhead box P1 (FOXP1) in transcriptional control of MSC senescence. In bone marrow MSCs, FOXP1 expression levels declined with age in an inverse manner with those of the senescence marker p16INK4A. Conditional depletion of Foxp1 in bone marrow MSCs led to premature aging characteristics, including increased bone marrow adiposity, decreased bone mass, and impaired MSC self-renewal capacity in mice. At the molecular level, FOXP1 regulated cell-fate choice of MSCs through interactions with the CEBPβ/δ complex and recombination signal binding protein for immunoglobulin κ J region (RBPjκ), key modulators of adipogenesis and osteogenesis, respectively. Loss of p16INK4A in Foxp1-deficient MSCs partially rescued the defects in replication capacity and bone mass accrual. Promoter occupancy analyses revealed that FOXP1 directly represses transcription of p16INK4A. These results indicate that FOXP1 attenuates MSC senescence by orchestrating their cell-fate switch while maintaining their replicative capacity in a dose- and age-dependent manner.

Authors

Hanjun Li, Pei Liu, Shuqin Xu, Yinghua Li, Joseph D. Dekker, Baojie Li, Ying Fan, Zhenlin Zhang, Yang Hong, Gong Yang, Tingting Tang, Yongxin Ren, Haley O. Tucker, Zhengju Yao, Xizhi Guo

×

Figure 6

Foxp1 attenuates MSC senescence through repression of p16INK4A transcription.

Options: View larger image (or click on image) Download as PowerPoint

Foxp1 attenuates MSC senescence through repression of p16INK4A transcri...
(A) Promoter occupancy of p16INK4A as assessed by anti-FOXP1 ChIP-PCR in MSCs. Sequence analysis identified a consensus FOXP1-binding site within the p16INK4A promoter (1701-1695). (B) FOXP1 repression of p16INK4A transcription as revealed by p16-Luc reporter assays in C3H10T1/2 cells transfected with the indicated levels of cotransfected FOXP1. (C) FOXP1 repressed transcription of p16-Luc reporter, but not the mutant reporter p16-Luc (mut). (D) Doubling times of BM MSCs expanded in vitro. The replication capacity of Foxp1Prx1Δ/Δ p16–/– double mutants is significantly higher than that of Foxp1Prx1Δ/Δ single mutants, but lower than that of control mice. n = 4. (E) Representative images of μCT analyses of trabecular bones of tibia in 3-month single (Foxp1Prx1Δ/Δ) and double (Foxp1Prx1Δ/Δ p16–/–) mutants. (F) Bone volume, BMD, and number of trabecular bones are significantly rescued in Foxp1Prx1Δ/Δ p16–/– double-mutant compared with Foxp1Prx1Δ/Δ single-mutant mice. n = 4. *P < 0.05; **P < 0.01; ***P < 0.001. Tb. BV/TV, trabecular bone volume/total volume; Tb. N, trabecular number; Tb. Sp, trabecular spacing; Tb. Th, trabecular thickness.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts